Impact of Early PCSK9 Inhibitor Treatment on Heart After Acute Myocardium Infarction
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, prospective, randomized, controlled study. The patients with STEMI
who were to undergo PPCI were divided into PCSK9 inhibitor group (n=80) and conventional
treatment group (n=80) using the interactive web response system (IWRS), at a 1:1 ratio. In
the PCSK9 inhibitor group, a dose of PCSK9 inhibitor (alirocumab) was injected subcutaneously
immediately after PPCI and was administered every two weeks thereafter for 3 months; the
control group received conventional treatment. Cardiac Magnetic Resonance Imaging (MRI) were
used to measure myocardial salvage index at 1 week after operation as primary endpoints.
Eject fraction at 6 months after operation will also be measured by MRI as secondary
endpoints. Serum TnI/T，CKMB levels were detected q8h for three times and and LDL-C levels
were detected at 1 month, 3 months and 6 months after operation. Blood inflammation
indicators were detected before and 1 week after the operation, and 6 months after the
operation.